Amgen Inc. (BVMF:AMGN34)

Market Cap	838.42B
Revenue (ttm)	190.26B
Net Income (ttm)	36.07B
Shares Out	n/a
EPS (ttm)	66.64
PE Ratio	23.25
Forward PE	13.81
Dividend	1.29 (2.20%)
Ex-Dividend Date	May 15, 2025

Volume	5
Average Volume	57
Open	58.62
Previous Close	60.07
Day's Range	58.51 - 58.86
52-Week Range	52.50 - 75.12
Beta	0.48
RSI	35.88
Earnings Date	Aug 4, 2025

About Nevro

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascul...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1980
• Employees: 28,000
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: AMGN34

Financial Performance

In 2024, Amgen's revenue was $33.42 billion, an increase of 18.57% compared to the previous year's $28.19 billion. Earnings were $4.09 billion, a decrease of -39.11%.